1%). For the LPV/r group the main reason was AEs (12.7%). The difference in discontinuation rates between the two treatment groups was mostly a result of the different rate of discontinuations because of AEs (4.7% with DRV/r and 12.7% with LPV/r; P = 0.005); this trend had been observed at week 48 and week 96 [6,7]. All other reasons for discontinuation were observed with comparable frequency between the two treatment groups (Table 1). At week 192, 68.8% of patients randomized to receive DRV/r and 57.2% of those randomized to receive LPV/r had a confirmed HIV-1 RNA < 50 copies/mL (ITT-TLOVR) (Fig. 1a). The estimated difference between the two groups was 11.6% (95% CI 4.4;

18.8%), thus demonstrating noninferiority of DRV/r to LPV/r (P < 0.001). Statistical superiority of DRV/r vs. LPV/r was also shown at week 192 (P = 0.002). Similar results were obtained for the Afatinib price sensitivity analyses (Fig. 1b). In an analysis where patients were censored out after they discontinued

treatment for any reason other than VF, the 192-week virological response rate remained higher in the DRV/r arm compared with LPV/r [87.4% (236 of 270) vs. 80.8% (198 of 245), respectively; P= 0.040; Fig. 1b]. Of the patients in the DRV/r arm with a confirmed virological response of < 50 copies/mL at week 48, 81.3% remained with HIV-1 RNA < 50 copies/mL at week 192. Of the patients in the LPV/r arm with a confirmed virological response < 50 copies/mL at week 48, 68.5% remained with < 50 copies/mL at week 192. Between week Ixazomib molecular weight 48 and week 192, 28 patients in the DRV/r arm and 34 patients in the LPV/r arm who were virologically Selleck CAL-101 suppressed at the week 48 analysis had a virological rebound at the week 192 analysis. At week 192, 75.2% of patients randomized to receive DRV/r vs. 65.0% of those randomized to receive LPV/r had a confirmed HIV-1 RNA < 400 copies/mL (ITT-TLOVR). The estimated difference between the two groups was 10.1%

(95% CI 3.2; 16.9%), thus demonstrating noninferiority of DRV/r to LPV/r (P < 0.001) and also statistical superiority (P = 0.004). The week 192 analysis of the virological response by baseline HIV-1 RNA (< or ≥ 100 000 copies/mL) showed that both subgroups randomized to receive DRV/r had a statistically superior virological response (HIV-1 RNA < 50 copies/mL; ITT-TLOVR) compared with those randomized to receive LPV/r [baseline HIV-1 RNA < 100 000 copies/mL: 69.5% vs. 60.2% (P = 0.038; estimated difference in response 9.3%; 95% CI 0.5; 18.1%), respectively; baseline HIV-1 RNA ≥ 100 000 copies/mL: 67.5% vs. 51.7% (P = 0.012; estimated difference in response 15.9%; 95% CI 3.5; 28.3%), respectively; Fig. 2]. Analysis by baseline CD4 count (< and ≥ 200 cells/μL) showed that patients with baseline CD4 count ≥ 200 cells/μL randomized to receive DRV/r had statistically superior virological response rates vs. those randomized to receive LPV/r (71.3% vs.